Economic evaluation of empirical antisecretory therapy versus Helicobacter pylori for management of dyspepsia: A randomized trial in primary care

International Journal of Technology Assessment in Health Care

Volumn 22, Issue 3, 2006, Pages 362-371

  Jarbol, Dorte Ejg ^a,c   Bech, Mickael ^b,c   Kragstrup, Jakob ^c   Havelund, Troels ^c,d,e   De Muckadell, Ove B Schaffalitzky ^c,e  

^a Research Unit for General Practice   (Denmark)

^b Institute of Public Health   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d Department of Neurology   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antiulcer agents; Dyspepsia; Healthcare costs; Helicobacter pylori; Primary health care

Indexed keywords

ANTIULCER AGENTS; DYSPEPSIA; HEALTHCARE COSTS; HELICOBACTER PYLORI; PRIMARY HEALTH CARE;

COST EFFECTIVENESS; COSTS; ECONOMIC AND SOCIAL EFFECTS; HEALTH CARE; PATIENT TREATMENT;

DISEASES;

STOMACH SECRETION INHIBITOR;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENMARK; DYSPEPSIA; ECONOMIC EVALUATION; EMPIRICISM; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; GENERAL PRACTICE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE;

ADULT; ANTI-ULCER AGENTS; COST-BENEFIT ANALYSIS; DYSPEPSIA; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES;

EID: 33749119997     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462306051269     Document Type: Article

References (93)

1. Agreus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics. 2002;20:347-355.
2. Agreus L, Svardsudd K, Nyren O, Tibblin G. The epidemiology of abdominal symptoms: Prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study. Scand J Gastroenterol. 1994;29:102-109.
3. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology. 1995;109:671-680.
4. Allison JE, Hurley LB, Hiatt RA, et al. A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: Clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease. Arch Intern Med. 2003;163:1165-1171.
5. Arents NL, Thijs JC, van Zwet AA, et al. Approach to treatment of dyspepsia in primary care: A randomized trial comparing "test-and- treat" with prompt endoscopy. Arch Intern Med. 2003;163:1606-1612.
6. Axon AT, O'Morain CA, Bardhan KD, et al. Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. BMJ. 1997;314:565-568.
7. Bech M, Gyrd-Hansen D. Cost implications of routine mammography screening of women 50-69 years in the county of Funen, Denmark. Health Policy. 2000;54:125-141.
8. Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med. 1998;339:1875-1881.
9. Briggs A, Andrew H. Handling uncertainty in economics evaluation and presenting the results. In: Drummond M, McGuire A, eds. Oxford: Oxford University Press; 2001.
10. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Econ 1994;3:95-104.
11. Briggs AH, Sculpher MJ, Logan RP, et al. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ. 1996;312:1321-1325.
12. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Econ. 1997;6:327-340.
13. Bruley D, V, Flejou JF, Colin R, et al. There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther. 2001;15:1177-1185.
14. Bytzer P. Diagnostic approach to dyspepsia. Best Pract Res Clin Gastroenterol. 2004;18:681-693.
15. Bytzer P, Aalykke C, Rune S, et al. Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group. Scand J Gastroenterol. 2000;35:1023-1032.
16. Bytzer P, Talley NJ. Dyspepsia. Ann Intern Med. 2001;134:815-822.
17. Chey WD, Moayyedi P. Uninvestigated dyspepsia and nonulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy. Aliment Pharmacol Ther. 2004;19(Suppl 1):1-8.
18. Chiba N, Van Zanten SJ, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: The Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ. 2002;324:1012-1016.
19. Chiba N, Veldhuyzen van Zanten SJ, Escobedo S, et al. Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. Aliment Pharmacol Ther. 2004;19:349-358.
20. Ciociola AA, McSorley DJ, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol. 1999;94:1834-1840.
21. Delaney B, Moayyedi P, Deeks J, et al. Themanagement of dyspepsia: A systematic review. Health Technol Assess. 2000;4:iii-189.
22. Delaney BC. Dyspepsia management in the millennium: To test and treat or not? Gut. 2003;52:10-11.
23. Delaney BC, Ford AC, Forman D, et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev. 2005;CD001961.
24. Delaney BC, Moayyedi P, Logan RF. Dyspepsia results may not apply in primary care. BMJ. 2003;327:811.
25. Dimenas E, Glise H, Hallerback B, et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30:1046-1052.
26. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: A cost-utility study. J Fam Pract. 1997;44:545-555.
27. Farkkila M, Sarna S, Valtonen V, Sipponen P. Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. Scand J Gastroenterol. 2004;39:327-335.
28. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med. 1995;123:260-268.
29. Fennerty MB. Review article: Helicobacter pylori and uninvestigated dyspepsia. Aliment Pharmacol Ther. 2002;16(Suppl 1):52-57.
30. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ. 2004;13:405-415.
31. Forbes GM, Glaser ME, Cullen DJ, et al. Duodenal ulcer treated with Helicobacter pylori eradication: Seven-year follow-up. Lancet. 1994;343:258-260.
32. Froehlich F, Gonvers JJ, Wietlisbach V, et al. Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. Am J Gastroenterol. 2001;96:2329-2336.
33. Garcia-Altes A, Jovell E. Economic analysis of treatment of functional dyspepsia. An assessment of the quality of published studies. Int J Technol Assess Health Care. 2001;17:517-527.
34. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992;116:705-708.
35. Hansen JM, Bytzer P, Schaffalitzky de Muckadell OB. Management of dyspeptic patients in primary care. Value of the unaided clinical diagnosis and of dyspepsia subgrouping. Scand J Gastroenterol. 1998;33:799-805.
36. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: A systematic review. Scand J Gastroenterol Suppl. 1999;231:3-8.
37. Heikkinen M, Pikkarainen P, Takala J, Julkunen R. General practitioners' approach to dyspepsia. Survey of consultation frequencies, treatment, and investigations. Scand J Gastroenterol. 1996;31:648-653.
38. Heikkinen M, Pikkarainen P, Takala J, et al. Etiology of dyspepsia: Four hundred unselected consecutive patients in general practice. Scand J Gastroenterol. 1995;30:519-523.
39. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review. Gastroenterology. 1996;110:1244-1252.
40. Hsu PI, Lai KH, Tseng HH, et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther. 2001;15:195-201.
41. Jarbol DE, Kragstrup J, Stovring H, et al. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. Am J Gastroenterol. 2006, in press.
42. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ. 1989;298:30-32.
43. Jones RH, Lydeard SE, Hobbs FD, et al. Dyspepsia in England and Scotland. Gut. 1990;31:401-405.
44. Kay L, Jorgensen T. Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors. Scand J Gastroenterol. 1994;29:2-6.
45. Kernick D. Costing interventions in primary care. Fam Pract. 2000;17:66-70.
46. Kernick DP, Netten A. A methodological framework to derive the cost of the GP consultation. Fam Pract. 2002;19:500-503.
47. Knill-Jones RP. Geographical differences in the prevalence of dyspepsia. Scand J Gastroenterol Suppl. 1991;182:17-24.
48. Koelz HR, Arnold R, Stolte M, et al. Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: A double blind randomised trial with a six month follow-up. Gut. 2003;52:40-46.
49. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 1996;10:460-466.
50. Koopmanschap MA, Rutten FF. The consequence of production loss or increased costs of production. Med Care. 1996;34:DS59-DS68.
51. Kristiansen IS, Gyrd-Hansen D. Cost-effectiveness analysis based on the number-needed-to-treat: Common sense or non-sense? Health Econ. 2004;13:9-19.
52. Ladabaum U, Chey WD. Uninvestigated Dyspepsia. Curr Treat Options Gastroenterol. 2002;5:125-131.
53. Ladabaum U, Chey WD, Scheiman JM, Fendrick AM. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: A cost-minimization analysis. Aliment Pharmacol Ther. 2002;16:1491-1501.
54. Ladabaum U, Fendrick AM, Glidden D, Scheiman JM. Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States. Am J Gastroenterol. 2002;97:3007-3014.
55. Laheij RJ, Severens JL, Jansen JB, et al. Management in general practice of patients with persistent dyspepsia. A decision analysis. J Clin Gastroenterol. 1997;25:563-567.
56. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001;134:361-369.
57. Lassen A, Hallas J, de Muckadell OB. Eradication of Helicobacter pylori and use of antisecretory drugs: Population based cohort study. BMJ. 2003;327:603.
58. Lassen AT, Hallas J, Schaffalitzky de Muckadell OB. Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial. Gut. 2004;53:1758-1763.
59. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: A randomised trial. Lancet. 2000;356:455-460.
60. Leodolter A, Kulig M, Brasch H, et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15:1949-1958.
61. Makris N, Barkun A, Crott R, Fallone CA. Cost-effectiveness of alternative approaches in the management of dyspepsia. Int J Technol Assess Health Care. 2003;19:446-464.
62. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-180.
63. Mandelblatt JS, Fryback DG, Weinstein MC, et al. Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med. 1997;12:551-558.
64. Manes G, Menchise A, De Nucci C, Balzano A. Empirical prescribing for dyspepsia: Randomised controlled trial of test and treat versus omeprazole treatment. BMJ. 2003;326:1118.
65. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988;2:1437-1442.
66. McColl K, Murray L, El Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869-1874.
67. McColl KE, Dickson A, El Nujumi A, et al. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: Impact of gastroesophageal reflux disease. Am J Gastroenterol. 2000;95:101-105.
68. McColl KE, Murray LS, Gillen D, et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia. BMJ. 2002;324:999-1002.
69. Miwa H, Hirai S, Nagahara A, et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2000;14:317-324.
70. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia (Cochrane Review). Cochrane Database Syst Rev. 2005(1)CD002096.
71. Nyren O, Adami HO, Gustavsson S, Loof L. Excess sicklisting in nonulcer dyspepsia. J Clin Gastroenterol. 1986;8:339-345.
72. Nyren O, Lindberg G, Lindstrom E, et al. Economic costs of functional dyspepsia. Pharmacoeconomics. 1992;1:312-324.
73. Ofman JJ, Etchason J, Fullerton S, et al. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: Clinical and economic consequences. Ann Intern Med. 1997;126:280-291.
74. Olsen AD. Combined empiric treatment and specific H. Pylori screening and treatment decrease the cost of evaluating epigastric abdominal pain. Gastroenterology. 1998;114:A248.
75. Penston JG, Pounder RE. A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther. 1996;10:83-89.
76. Peura DA. The problem of Helicobacter pylori-negative idiopathic ulcer disease. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:109-117.
77. Rabeneck L, Wray NP, Graham DY. Managing dyspepsia: What do we know and what do we need to know? Am J Gastroenterol. 1998;93:920-924.
78. Rothenbacher D, Brenner H. Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: Recent developments and future implications. Microbes Infect. 2003;5:693-703.
79. Savarino V, Vigneri S, Celle G. The 13C urea breath test in the diagnosis of Helicobacter pylori infection. Gut. 1999;45(Suppl 1):I18-I22.
80. Severens JL, Laheij RJ, Jansen JB, et al. Estimating the cost of lost productivity in dyspepsia. Aliment Pharmacol Ther. 1998;12:919-923.
81. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: A decision analysis. Gastroenterology. 1996;110:72-83.
82. Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: A decision analysis of competing strategies. Gastroenterology. 2002;122:1270-1285.
83. Stevens VJ, Shneidman RJ, Johnson RE, et al. Helicobacter pylori eradication in dyspeptic primary care patients: A randomized controlled trial of a pharmacy intervention. West J Med. 2002;176:92-96.
84. Talley NJ. Dyspepsia management in the millennium: The death of test and treat? Gastroenterology. 2002;122:1521-1525.
85. Talley NJ, Axon A, Bytzer P, et al. Management of uninvestigated and functional dyspepsia: A Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther. 1999;13:1135-1148.
86. Talley NJ, Janssens J, Lauritsen K, et al. Eradication of Helicobacter pylori in functional dyspepsia: Randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ. 1999;318:833-837.
87. Talley NJ, Silverstein MD, Agreus L, et al. AGA technical review: Evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology. 1998;114:582-595.
88. Talley NJ, Vakil N, Ballard ED, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med. 1999;341:1106-1111.
89. Tan AC, Hartog GD, Mulder CJ. Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication. Aliment Pharmacol Ther. 1999;13:1519-1522.
90. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, et al. Design of treatment trials for functional gastrointestinal disorders. Gut. 1999;45(Suppl 2):II69-II77.
91. Ware JE Jr. SF-36 health survey update. Spine. 2000;25:3130-3139.
92. Westbrook JI, Duggan AE, McIntosh JH. Prescriptions for antiulcer drugs in Australia: Volume, trends, and costs. BMJ. 2001;323:1338-1339.
93. Xia HH, Phung N, Altiparmak E, et al. Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in Western Sydney between 1990 and 1998. Dig Dis Sci. 2001;46:2716-2723.